BioMarin Pharmaceutical (BMRN): Assessing Valuation Following Robust Q3 Growth and Upgraded Full-Year Guidance

Simply Wall St.11-27

BioMarin Pharmaceutical (BMRN) grabbed attention after its Q3 update, where it reported solid revenue growth and raised its full-year guidance higher than any of its peers. The big drivers were its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586216520?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-27 11:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586216520","market":"sg","top_or_hot":-1,"title":"BioMarin Pharmaceutical (BMRN): Assessing Valuation Following Robust Q3 Growth and Upgraded Full-Year Guidance","media":"Simply Wall St.","content":"<div>\n<p>BioMarin Pharmaceutical (BMRN) grabbed attention after its Q3 update, where it reported solid revenue growth and raised its full-year guidance higher than any of its peers. The big drivers were its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/biomarin-pharmaceutical-bmrn-assessing-valuation-following-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Pharmaceutical (BMRN): Assessing Valuation Following Robust Q3 Growth and Upgraded Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Pharmaceutical (BMRN): Assessing Valuation Following Robust Q3 Growth and Upgraded Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-27 11:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/biomarin-pharmaceutical-bmrn-assessing-valuation-following-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioMarin Pharmaceutical (BMRN) grabbed attention after its Q3 update, where it reported solid revenue growth and raised its full-year guidance higher than any of its peers. The big drivers were its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/biomarin-pharmaceutical-bmrn-assessing-valuation-following-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMRN","symbol_name":"拜玛林制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/biomarin-pharmaceutical-bmrn-assessing-valuation-following-r","article_id":"2586216520","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/biomarin-pharmaceutical-bmrn-assessing-valuation-following-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586216520","pubTimestamp":1764213636,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BioMarin Pharmaceutical (BMRN) grabbed attention after its Q3 update, where it reported solid revenue growth and raised its full-year guidance higher than any of its peers. The big drivers were its PALYNZIQ and VOXZOGO products, each delivering over 20% revenue growth.\nSee our latest analysis for BioMarin Pharmaceutical.\nBioMarin’s latest quarterly momentum has drawn a spotlight, but the share price tells a more cautious story. At $55.52, the 1-year total shareholder return is still down 15%,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BMRN":"拜玛林制药"},"translate_title":"拜玛林制药(BMRN)：在第三季度强劲增长并上调全年指引后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1.5},"content_text":"BioMarin Pharmaceutical (BMRN) grabbed attention after its Q3 update, where it reported solid revenue growth and raised its full-year guidance higher than any of its peers. The big drivers were its PALYNZIQ and VOXZOGO products, each delivering over 20% revenue growth. See our latest analysis for BioMarin Pharmaceutical. BioMarin’s latest quarterly momentum has drawn a spotlight, but the share price tells a more cautious story. At $55.52, the 1-year total shareholder return is still down 15%, and the long-term three-year return has lagged by 46%. Short bursts of optimism, like this week’s 5.8% share price gain, have not reversed the broader downward trend, suggesting the market remains in wait-and-see mode despite new product wins and improved guidance. If BioMarin’s surge in revenue growth has you thinking bigger, it’s worth checking out companies with similarly bold ambitions in life sciences — See the full list for free. So after a tough stretch for the shares, does BioMarin’s recent momentum signal a buying opportunity, or is the market already anticipating the company’s next phase of growth? AdvertisementMost Popular Narrative: 39% Undervalued BioMarin's most widely followed narrative values the stock far above its last closing price, hinting at a disconnect between fundamentals and recent market sentiment. This valuation sets the stage for a closer look at the bullish reasoning behind it.  Expanding global demand, new therapies, and strategic acquisitions strengthen BioMarin's revenue growth, market reach, and future pipeline potential. Operational efficiency, disciplined cost management, and regulatory advantages support sustained profitability and long-term margin stability.  Read the complete narrative. Curious how BioMarin’s story supports such a high target? It comes down to surprising forecasts for revenue and profit margins, plus big assumptions on future earnings multiples. Discover the full rationale—one key assumption might change everything you think about the company’s prospects. Result: Fair Value of $90.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent competition and potential pipeline setbacks could quickly challenge this undervalued thesis. This keeps uncertainty high for both revenue and profit expectations. Find out about the key risks to this BioMarin Pharmaceutical narrative.  Build Your Own BioMarin Pharmaceutical Narrative If you see things differently or want to dig into the data yourself, crafting your own BioMarin story takes less than three minutes. Do it your way A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding BioMarin Pharmaceutical. Looking for More Smart Opportunities? Don’t let new breakthroughs pass you by. Thoughtfully hand-pick the stocks that match your goals by browsing powerful screening ideas right now.  Uncover strong, income-generating plays and seize the chance to tap into steady yield with these 15 dividend stocks with yields > 3% offering consistent payouts above 3%. Expand your watchlist to pioneers in artificial intelligence by searching through these 25 AI penny stocks and join early on sector-defining innovation. Spot high-potential companies trading below their worth and take action with these 927 undervalued stocks based on cash flows, maximizing your shot at value investing wins.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioMarin Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586216520","isCrawlerRequest":true}